NCT04789915View on ClinicalTrials.gov

Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis

PHASE1RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

May 26, 2021

Primary Completion Date

July 1, 2025

Study Completion Date

December 31, 2026

Conditions
PsychosisNegative Symptoms With Primary Psychotic Disorder
Interventions
DRUG

Memantine

Add on treatment with memantine to aripiprazole.

DRUG

Placebo

Placebo add on to aripiprazole

Trial Locations (1)

2600

RECRUITING

Centre for Neuropsychiatric Schizophrenia Research, CNSR & Centre for Clinical Intervention & Neuropsychiatric Schizophrenia Research, CINS, Glostrup Municipality

All Listed Sponsors
collaborator

Lundbeck Foundation

OTHER

collaborator

Danish Research Centre for Magnetic Resonance

OTHER

lead

Bjorn H. Ebdrup

OTHER

NCT04789915 - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis | Biotech Hunter | Biotech Hunter